Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CapsoVision, Inc. is a medical technology company specializing in capsule endoscopy systems used for non-invasive visualization of the gastrointestinal (GI) tract, particularly the small bowel. The company operates within the medical devices and diagnostic imaging industries, serving hospitals, gastroenterology clinics, and diagnostic centers. Its primary revenue driver is the sale of capsule endoscopy systems, including disposable imaging capsules, proprietary software, and related hardware platforms.
The company is uniquely positioned through its panoramic imaging technology, which captures a 360-degree view of the small intestine without requiring external sensors or belts, differentiating it from traditional capsule endoscopy competitors. CapsoVision was founded in 2006 and evolved from an R&D-focused startup into a commercial-stage medical device company following regulatory clearances in the U.S. and international markets. Its growth has been driven by increasing clinical adoption of minimally invasive diagnostic tools and broader acceptance of capsule-based GI diagnostics.
Business Operations
CapsoVision’s core business centers on its Capsule Endoscopy Systems segment, which includes the CapsoCam Plus® capsule, proprietary image retrieval hardware, and diagnostic review software. Revenue is primarily generated through the sale of single-use capsules and supporting systems to healthcare providers, creating a recurring-use model tied to procedure volumes.
Operations span both domestic and international markets, with regulatory clearances supporting sales in the United States and multiple foreign jurisdictions. The company controls its core imaging technology, optical design, and data storage architecture, which stores images internally within the capsule rather than transmitting them wirelessly. CapsoVision does not publicly disclose extensive joint ventures, but it utilizes distribution partnerships in select international markets and maintains manufacturing and quality systems aligned with medical device regulatory standards.
Strategic Position & Investments
CapsoVision’s strategic direction emphasizes expanding clinical indications, improving image resolution and workflow efficiency, and increasing market penetration in both established and emerging healthcare markets. Growth initiatives have focused on next-generation capsule development, software enhancements leveraging automated image review, and broadening physician awareness of panoramic capsule endoscopy.
The company has historically pursued organic growth rather than large-scale acquisitions, and publicly available sources do not confirm material acquisitions or diversified portfolio investments. Its strategic investments are concentrated in internal R&D, regulatory approvals, and intellectual property related to optical imaging and capsule miniaturization. The company remains focused on diagnostic gastroenterology rather than adjacent therapeutic or pharmaceutical sectors.
Geographic Footprint
CapsoVision is headquartered in Saratoga, California, within North America, and serves as its primary center for executive leadership, research, and corporate operations. The company maintains a commercial presence across North America, Europe, and parts of Asia, supported by regional distributors and regulatory clearances.
Its international influence is primarily operational rather than investment-based, with sales extending to healthcare providers in multiple countries that recognize U.S. or European medical device standards. While global in reach, CapsoVision remains a relatively concentrated organization compared to large multinational medical device firms, with most strategic control retained at its U.S. headquarters.
Leadership & Governance
CapsoVision was founded by entrepreneurs and engineers with backgrounds in medical imaging and optical technology. Leadership has emphasized innovation, physician-centric design, and clinically validated performance as core elements of the company’s governance and strategic vision.
Key executives include:
- Frank Wang – Founder and Chief Executive Officer
- John Zhao – Chief Technology Officer
- David Chen – Chief Operating Officer
- Mark Schmidt – Vice President of Sales and Marketing
The leadership philosophy centers on disciplined growth, regulatory compliance, and long-term clinical adoption rather than rapid diversification. Data inconclusive based on available public sources regarding board composition and independent director structure.